NCT06503042View on ClinicalTrials.gov

A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Chemotherapy combined with immunotherapy

Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.

DRUG

Chemotherapy only

Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.

All Listed Sponsors
lead

Tang-Du Hospital

OTHER

NCT06503042 - A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC | Biotech Hunter | Biotech Hunter